Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Accelerate Diagnostics, IncAXDX · Entity 78156 | Director · Chief Executive Officer | April 04, 2025 | April 07, 2025 |
| BRUKER CORPBRKR · Entity 3609 | Director | February 15, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Accelerate Diagnostics, Inc
Report date April 04, 2025 · Filed April 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 191,374 |
Ending reported balance
After 2025-04-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-04-04 · Exercise / conversion · Acquired 53,283 · Balance 216,717 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. Row 2 · 2025-04-04 · Sale · Disposed 25,343 · Balance 191,374 F2: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. |
| Employee Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-04-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-04 · Exercise / conversion · Disposed 53,283 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. F3: On April 4, 2022, the reporting person was granted a total of 88,806 RSUs, of which 40% vest on April 4, 2024 and the remaining 60% vest on April 4, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting.
F2: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.
F3: On April 4, 2022, the reporting person was granted a total of 88,806 RSUs, of which 40% vest on April 4, 2024 and the remaining 60% vest on April 4, 2025.
BRUKER CORP
Report date February 15, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,520 |
Reported balance
After 2026-02-15 transaction · row 1
1 source rowRow 1 · 2026-02-15 · Grant · Acquired 4,520 · Balance 4,520 F1: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on February 15, 2027. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on February 15, 2027. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2020 Filed Mar 27, 2020 21:02 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GrantEmployee Restricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-004258 · wf-form4_158535735752030.xml · derivative · entry 1 Phillips Jack · CIK 0001784805 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · date: This Form 4 was inadvertently not filed within the required time following the transaction date of February 1, 2020. F3 · derivative.exercise_date: The reporting person received restricted stock units, of which vests in equal annual amounts on each anniversary of the grant date over five years, beginning on February 1, 2021 and ending on February 1, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F4 · derivative.expiration_date: Not Applicable. Read SEC document |
| January 01, 2020 Filed Mar 27, 2020 21:03 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GrantEmployee Stock Option (right to buy) · Derivative | 25,268 | $3.96 Strike: $16.90 | $100,061.28 |
DisclosureSEC source: 0001628280-20-004259 · wf-form4_158535737987631.xml · derivative · entry 1 Phillips Jack · CIK 0001784805 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,268 Underlying: Common Stock · 25,268 shares Expires 2030-01-01 F1 · date: This Form 4 was inadvertently not filed within the required time following the transaction date of January 1, 2020. F3 · price: The options were issued to the reporting person under the 2020 Salary Waiver and Nonqualified Stock Option Grant Plan (the "Sub-Plan") established pursuant to the Accelerate Diagnostics, Inc. 2012 Omnibus Equity Incentive Plan. Pursuant to the terms of the Sub-Plan, the reporting person irrevocably waived $100,000 of base compensation scheduled to be paid to the reporting person in 2020 in exchange for such options. F2 · derivative.exercise_date: Option awards vest in equal monthly amounts over twelve months, with the first installment vesting on January 31, 2020. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 16:39 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GrantEmployee Stock Option (right to buy) · Derivative | 1,249,917 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001144204-19-038595 · tv526863_form4.xml · derivative · entry 1 Phillips Jack · CIK 0001784805 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,249,917 Underlying: Common Stock · 1,249,917 shares Expires 2029-08-06 F1 · derivative.exercise_date: 40% of the options vest on the second anniversary of the date of grant on August 6, 2020 and the remaining 60% of the options vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.